{"id":"bfdca0c8-412a-5758-a480-9c7adf5f75a0","stable_key":"44eaeae5-557a-552b-8998-884f30462e2a:sulforaphane-autism-secondary-abc","predicate":"improved_secondary","statement":"Caregiver ABC scores improved at 15 weeks, but SRS-2 did not significantly improve.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"0b974b5b-6a3c-58de-a2f4-b06286d86f4e","mechanism_event_label":"Different secondary measures gave different results.","subject":{"id":"367b5d3e-6202-538d-9c94-69b981089460","slug":"glucoraphanin-myrosinase-preparation","display_name":"Glucoraphanin plus active myrosinase preparation","entity_type_key":"chemical_species"},"object":{"id":"57835bb6-4a24-58d9-a078-cc228123f546","slug":"autism-abc-score","display_name":"Aberrant Behavior Checklist score, population specified","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0b974b5b-6a3c-58de-a2f4-b06286d86f4e","stable_key":"44eaeae5-557a-552b-8998-884f30462e2a:sulforaphane-autism-secondary-abc-event","event_type":"biochemical_relationship","label":"Different secondary measures gave different results.","description":"Caregiver ABC scores improved at 15 weeks, but SRS-2 did not significantly improve.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"367b5d3e-6202-538d-9c94-69b981089460","slug":"glucoraphanin-myrosinase-preparation","display_name":"Glucoraphanin plus active myrosinase preparation","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"57835bb6-4a24-58d9-a078-cc228123f546","slug":"autism-abc-score","display_name":"Aberrant Behavior Checklist score, population specified","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/sulforaphane-research/34034808.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4\", \"start_char\": 0, \"end_char\": 3223, \"text_sha256\": \"1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind trial followed by open-label and withdrawal phases","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Glucoraphanin plus active myrosinase tablets, not preformed sulforaphane; 15 weeks randomized, 15 weeks open-label, six weeks off","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Primary endpoint was nonsignificant. The published correction (PMID 34134777, DOI 10.1186/s13229-021-00451-9) clarifies the preparation: 34 micromol glucoraphanin per tablet, calculated to yield about 15 micromol sulforaphane. Open-label analyses are nonrandomized.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Sulforaphane research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"sulforaphane","display_name":"Sulforaphane / SFN, stereochemistry specified per study","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human, 57 children aged 3-12 randomized; 45 analyzed","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Different secondary measures gave different results.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[sulforaphane-p34034808] Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. (2021). https://pubmed.ncbi.nlm.nih.gov/34034808/ DOI: 10.1186/s13229-021-00447-5","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Primary OACIS and secondary caregiver ratings","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"4ce6384a-a53f-5c96-95a3-0da65e630b84","evidence_kind":"source_excerpt","locator":"Lines 1373-1384","start_line":1373,"end_line":1384,"excerpt":"### sulforaphane-autism-secondary-abc\nCaregiver ABC scores improved at 15 weeks, but SRS-2 did not significantly improve.\nCondition category: normal\nnutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Different secondary measures gave different results.\norganism: Human, 57 children aged 3-12 randomized; 45 analyzed\ntissue_or_cell_type: Primary OACIS and secondary caregiver ratings\nexperimental_model: Randomized double-blind trial followed by open-label and withdrawal phases\nlimitations: Primary endpoint was nonsignificant. The published correction (PMID 34134777, DOI 10.1186/s13229-021-00451-9) clarifies the preparation: 34 micromol glucoraphanin per tablet, calculated to yield about 15 micromol sulforaphane. Open-label analyses are nonrandomized.\nexposure: Glucoraphanin plus active myrosinase tablets, not preformed sulforaphane; 15 weeks randomized, 15 weeks open-label, six weeks off\nevidence_span: {\"source_cache\": \"artifacts/sulforaphane-research/34034808.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4\", \"start_char\": 0, \"end_char\": 3223, \"text_sha256\": \"1b60b5ce85bab14b43239e810410dd230703600eac55bc8960c621ae7de881a4\"}\n[sulforaphane-p34034808] Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. (2021). https://pubmed.ncbi.nlm.nih.gov/34034808/ DOI: 10.1186/s13229-021-00447-5","model_system":"Randomized double-blind trial followed by open-label and withdrawal phases","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [sulforaphane-p34034808] Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. (2021). https://pubmed.ncbi.nlm.nih.gov/34034808/ DOI: 10.1186/s13229-021-00447-5","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a4bafbf7-f117-53c9-a6d7-8fb25e4aca72","stable_key":"import-44eaeae5-557a-552b-8998-884f30462e2a","title":"Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f355c492a6c35673d8260b1328667fe206e5315b9fcaa5aeff53d80373c7ef97","revision_id":"f2c47d71-34cd-5160-8e92-fe196b576707","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}